A clinical trial of the p-glycoprotein antagonist, tariquidar (XR9576), in combination with docetaxel in patients with lung, ovarian, and cervical cancer: analysis of the interaction between tariquidar and docetaxel

Trial Profile

A clinical trial of the p-glycoprotein antagonist, tariquidar (XR9576), in combination with docetaxel in patients with lung, ovarian, and cervical cancer: analysis of the interaction between tariquidar and docetaxel

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2015

At a glance

  • Drugs Tariquidar (Primary) ; Docetaxel
  • Indications Cervical cancer; Lung cancer; Ovarian cancer
  • Focus Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Jul 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
    • 07 Jul 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top